AviadoBio

AviadoBio is a private, clinical-stage biotech pioneering gene therapies for neurodegenerative diseases, with its lead program AVB-101 in Phase 1/2 trials for frontotemporal dementia (FTD-GRN). The company's strategy is built on a deep understanding of neuroanatomy and a suite of proprietary platforms, including the vMiX™ RNA silencing platform, designed to overcome the critical delivery challenges in treating neurological disorders. Founded on research from King's College London and the UK Dementia Research Institute, AviadoBio is backed by a strong syndicate of life science investors and is led by an experienced team, including CEO Lisa Deschamps. The company is pre-revenue and is advancing a pipeline that also targets retinitis pigmentosa, Alzheimer's/tauopathies, and ALS.

Proprietary neuroanatomy-led gene therapy platform featuring the vMiX™ RNA silencing system, optimized constructs, novel capsids, and precision delivery technologies designed to target the brain, spinal cord, and retina.

AviadoBio competes in the rapidly evolving gene therapy space for neurodegenerative diseases, facing competition from both large pharma (e.g., Biogen, Novartis, Roche) and specialized biotechs (e.g., UniQure, Sio Gene Therapies, Passage Bio). In FTD and ALS, several companies are pursuing gene therapy, antisense oligonucleotide, and other modalities. Its differentiation hinges on its proprietary delivery technology and neuroanatomy-led approach, aiming to achieve superior biodistribution and targeting compared to standard intracranial delivery methods.